NCT00440531 - Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED) | Biotech Hunter

Enrollment

540

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Hepatitis B

Interventions

BIOLOGICAL

Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)

RECOMBIVAX HB™ (currently licensed product) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.

BIOLOGICAL

Comparator: Modified Process Hepatitis B Vaccine (Experimental)

Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.

BIOLOGICAL

Comparator: ENGERIX-B™ (currently licensed product)

ENGERIX-B™ given IM (Intramuscular) in 3 doses of 20 mcg (micrograms)/1.0 mL each over 6 months.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY